Rallybio Corp

Rallybio Corp.

Biotechnology • Healthcare • New Haven, CT, United States • RLYB (NCM)

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

203 859 3820 234 Church Street, New Haven, CT 06510, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances - Yahoo Finance
Yahoo Finance • Sep 21
Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal
Hartford Business Journal • Jul 8
Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha
Seeking Alpha • Jul 8
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
Business Wire • Sep 25
Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint - Fierce Biotech
Fierce Biotech • Apr 8

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Rallybio Corp had layoffs?
No layoff events have been recorded for Rallybio Corp in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Rallybio Corp have?
Rallybio Corp has approximately 15 employees.
What industry is Rallybio Corp in?
Rallybio Corp operates in the Biotechnology industry, within the Healthcare sector.
Is Rallybio Corp a publicly traded company?
Yes, Rallybio Corp is publicly traded under the ticker symbol RLYB on the NCM. The company has a market capitalization of approximately $0.03 billion.
Where is Rallybio Corp headquartered?
Rallybio Corp is headquartered in New Haven, CT, United States at 234 Church Street, New Haven, CT 06510, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.